Table 1.
Microarray datasets used in this study.
| *Desmedt et al. [20] (GSE7390)** |
van de Vijver et al. [11]** | *Loi et al. [21] (GSE6532) |
*Sabatier et al. [22] (GSE21653) |
*Schmidt et al. [23] (GSE11121) |
|
|---|---|---|---|---|---|
| Platform | HG-U133A | Agilent human genome | HG-U133A, HG-U133B | HG-U133Plus2.0 | HG-U133A |
| Samples | 198 | 295 | 327 | 255 | 200 |
| ER | |||||
| ER+ (no. of samples) | 134 | 226 | 263 | 150 | 156 |
| ER− (no. of samples) | 64 | 69 | 45 | 102 | 44 |
| Tumour grade | |||||
| Grade 1 (no. of samples) | 30 | — | 52 | 44 | 29 |
| Grade 2 (no. of samples) | 83 | — | 158 | 88 | 136 |
| Grade 3 (no. of samples) | 83 | — | 57 | 116 | 35 |
| Metastasis Free Survival | |||||
| Yes (no. of samples) | 62 | 101 | 70 | 81 | 46 |
| No (no. of samples) | 136 | 194 | 224 | 160 | 154 |
| Age (in Years) | |||||
| ≤40 (no. of samples) | 42 | — | 19 | 49 | — |
| 41–70 (no. of samples) | 156 | — | 241 | 171 | — |
| >70 (no. of samples) | 0 | — | 55 | 34 | — |
| Average (in Years) | 46 | — | 59 | 54 | — |
|
| |||||
| Total Samples | 1253 ( 929 (ER+) and 324 (ER−)) | ||||
|
| |||||
| Total samples selected in our Study (on the basis of histologic grade and receptor status) | 958 (703 (ER+) and 255 (ER−)) | ||||
Patients with missing histologic grade and estrogen receptor status based information are excluded from the training sets. *The datasets used in our training sets; **The testing sets.